[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":31,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":-5,"_48":49,"_50":-5,"_51":-5,"_52":53,"_54":55,"_56":57,"_58":42,"_59":42,"_60":61,"_62":42,"_63":64},"id","p0oscs43n0rhx8aokrnotsltg","revision",2,"title","Indivior 股东特别会议批准与并购相关的股份发行","originalTitle","Indivior Pharmaceuticals, Inc. (0001625297) (Filer)","summary","Indivior Pharmaceuticals 于 2026 年 10 月 15 日举行特别股东大会，批准了与并购相关的股份发行提案。截至 2026 年 9 月 4 日，公司有 1.18 亿股流通股，其中 91.2 亿股（占 77.27%）出席了会议。提案以 8545.6 万票赞成、556.4 万票反对获得通过。","reason","股东批准股份发行为并购交易完成扫清了关键程序障碍，但需关注后续监管审批及交易整合进展。","source",{"_12":88,"_89":90,"_9":91,"_92":42,"_93":94,"_95":96},"links",{"_85":86,"_78":87},"publishedAt","2026-10-15T20:17:53.000Z","discoveredAt","2026-10-15T22:49:56.723Z","timelineAt","category","ai-products","tags",[83,84],"stockSymbols",[82],"score",60,"selected",true,"channel","news","story",{"_73":74,"_16":75},"x","readingMode","full","author","language","body",{"_64":77,"_78":-5,"_79":80,"_81":42},"outline",[],"relatedStories",[76],"indexable","markdownAvailable","group",{"_65":66,"_45":67,"_68":69,"_70":71,"_72":71},"hasTranslation","bodyLanguage","zh","factId","f6t2ZWu8Z73E",{"_73":74,"_16":75},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","2cbdab9c-f240-4440-b2f5-6bc74d4984a8","Indivior与Supernus合并事件",{"_73":74,"_16":75},"

美国

证券交易委员会

华盛顿特区 20549

表格 8-K

当前报告

根据 1934 年证券交易法第 13 条或 15(d) 条

报告日期（报告最早事件的日期）：

2026 年 10 月 15 日

INDIVIOR PHARMACEUTICALS, INC.

（注册人确切名称，如其公司章程中所指定）

\n \n \n \n \n \n \n \n \n \n \n \n \n

特拉华州		001-37835		41-2520873
（注册地或其他管辖区）		（委员会文件编号）		（美国国税局雇主识别号）

\n \n \n \n \n \n \n \n \n

Midlothian Turnpike 10710 号，125 号套房

North Chesterfield，VA

23235

（主要行政办公地址）

（邮政编码）

(804) 379-1090

（注册人电话号码，包括区号）

不适用

（前名或前址，若自上次报告以来已变更）

勾选下列适当的方框，如果本 8-K 表格的提交旨在同时满足注册人根据以下任何条款的提交义务（见下文一般说明 A.2）：

\n \n \n \n

¨	根据证券法第 425 条规则（17 CFR 230.425）进行的书面通信

\n \n \n \n

¨	根据交易法第 14a-12 条规则（17 CFR 240.14a-12）进行的招揽材料

\n \n \n \n

¨	根据交易法第 14d-2(b) 条规则（17 CFR 240.14d-2(b)）进行的启动前通信

\n \n \n \n

¨	根据交易法第 13e-4(c) 条规则（17 CFR 240.13e-4(c)）进行的启动前通信

根据该法第 12(b) 条注册的证券：

\n \n \n \n \n \n \n \n \n \n \n \n \n

各类别名称		交易 \n符号		注册交易所名称 \n
普通股，每股面值 0.001 美元		INDV		纳斯达克股票市场有限责任公司

通过勾选标记表明注册人是否为根据 1933 年证券法第 405 条规则（本章 §230.405）或 1934 年证券交易法第 12b-2 条规则（本章 §240.12b-2）定义的“新兴增长公司”。

新兴增长公司 ¨

如果是新兴增长公司，通过勾选标记表明注册人是否已选择不使用为遵守交易法第 13(a) 条提供的任何新或修订的财务
\n会计准则而采用的延长过渡期。 ¨

\n \n \n \n

项目 5.07

将事项提交证券持有人表决。

2026年10月15日，Indivior Pharmaceuticals, Inc.（“Indivior”）举行了特别股东大会（“Indivior特别股东大会”）。\n\n2026年9月4日营业结束之时，即Indivior特别股东大会的登记日，共有118,031,934股Indivior普通股（“Indivior股份”）流通且有权在Indivior特别股东大会上投票，其中91,206,182股Indivior股份亲自出席或由代理人代表出席Indivior特别股东大会，占Indivior流通且有权投票的股份的77.27%，构成了召开Indivior特别股东大会的法定人数。在Indivior特别股东大会上，Indivior的股东批准了下述提案，该提案在Indivior于2026年9月11日向美国证券交易委员会提交的最终联合委托声明/招股说明书中进行了更详细的描述。关于第二项提案——批准Indivior特别股东大会延期至较晚日期或时间（如有必要或适当），包括延期以允许征集更多赞成Indivior股份发行提案（定义见下文）的选票或代理，如果在该次延期时赞成该提案的选票不足，则无需采取股东行动，且未就该提案进行投票。

Indivior特别股东大会审议并表决的提案的最终投票结果如下。

提案\n1：Indivior股份发行。 批准在合并协议规定的范围内发行Indivior股份，包括为了遵守纳斯达克规则5635的适用规定（“Indivior股份发行提案”）。

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

赞成		反对		弃权		经纪人不投票
85,455,705		5,563,744		186,733		N/A

签名

根据1934年《证券交易法》的要求，登记人已正式授权下述签字人代表其签署本报告。

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

		INDIVIOR PHARMACEUTICALS, INC.

日期：  2026年10月15日	签署人：	/s/ Ryan Preblick
		姓名：	Ryan Preblick
		职位：	首席财务官

","original","zhKind","translation","complete","INDV","公司与财报","并购","aihot","/items/p0oscs43n0rhx8aokrnotsltg","https://www.sec.gov/Archives/edgar/data/1625297/000110465926116253/0001104659-26-116253-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792368000&sig=7b6974b5a67903ec","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792368000&sig=85dc13f192a3fa85 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792368000&sig=7b2f7276301ea6d9 96w","changelogVersion","2026-10-01T08:00"]